BEVESPI AEROSPHERE

Glycopyrrolate/Formoterol

BEVESPI AEROSPHERE

LAMALABA MDI

Glycopyrrolate / Formoterol fumarate · AstraZeneca

Clinical Reference

Active Medication & Mechanism

Glycopyrrolate LAMA
9 mcg per actuation

Long-acting muscarinic antagonist. Blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction.
Formoterol fumarate LABA
4.8 mcg per actuation

Long-acting beta2-adrenergic agonist with rapid onset of action. Stimulates beta2-receptors, increasing cAMP and relaxing airway smooth muscle.

FDA-Approved Dosing by Indication

// approval varies by strength + age

COPD

1/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
9/4.8 mcg	Adults (≥18 years)	2 inhalations twice daily (morning and evening) Long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.	36/19.2 mcg	FDA Approved

9/4.8 mcg FDA Approved

Pop · Adults (≥18 years)

2 inhalations twice daily (morning and evening)

Long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

Total · 36/19.2 mcg

Asthma

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	All patients	—	—	Not Approved Bevespi Aerosphere is NOT indicated for asthma. LABA without ICS in asthma increases risk of serious events.

Any strength Not Approved

Pop · All patients

—

Total · — Bevespi Aerosphere is NOT indicated for asthma. LABA without ICS in asthma increases risk of serious events.

Acute Use

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	Acute bronchospasm / rescue	—	—	Not Approved Not indicated for relief of acute bronchospasm. Use a SABA.

Any strength Not Approved

Pop · Acute bronchospasm / rescue

—

Total · — Not indicated for relief of acute bronchospasm. Use a SABA.